At its July 2020 meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of eleven medicines:

  • 3 new anticancer drugs
  • 1 Janus kinase inhibitor for rheumatoid arthritis
  • 1 antibody for sickle-cell anaemia
  • 1 vaginal ring for HIV prevention
  • 1 combination of active ingredients for post-operative pain
  • 1 biosimilar bevacizumab
  • generic drugs.

The EU Commission will then decide whether the respective medicines will be part of the pharmaceutical market in the EU.